108 related articles for article (PubMed ID: 34139552)
1. Anti-neoplastic and demethylating activity of a newly synthetized flavanone-derived compound in Renal Cell Carcinoma cell lines.
Marques-Magalhães Â; Graça I; Miranda-Gonçalves V; Henrique R; Lopez M; Arimondo PB; Jerónimo C
Biomed Pharmacother; 2021 Sep; 141():111681. PubMed ID: 34139552
[TBL] [Abstract][Full Text] [Related]
2. Dauricine inhibits viability and induces cell cycle arrest and apoptosis via inhibiting the PI3K/Akt signaling pathway in renal cell carcinoma cells.
Zhang S; Ren Y; Qiu J
Mol Med Rep; 2018 May; 17(5):7403-7408. PubMed ID: 29568902
[TBL] [Abstract][Full Text] [Related]
3. Salinomycin suppresses cancer cell stemness and attenuates TGF-β-induced epithelial-mesenchymal transition of renal cell carcinoma cells.
Liu L; Wang Q; Mao J; Qin T; Sun Y; Yang J; Han Y; Li L; Li Q
Chem Biol Interact; 2018 Dec; 296():145-153. PubMed ID: 30273566
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of novel 3-halo-3-nitroflavanones and their activities as DNA methyltransferase inhibitors in cancer cells.
Pechalrieu D; Dauzonne D; Arimondo PB; Lopez M
Eur J Med Chem; 2020 Jan; 186():111829. PubMed ID: 31757526
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of bcl-2 enhances the efficacy of chemotherapy in renal cell carcinoma.
Kausch I; Jiang H; Thode B; Doehn C; Krüger S; Jocham D
Eur Urol; 2005 May; 47(5):703-9. PubMed ID: 15826766
[TBL] [Abstract][Full Text] [Related]
6. Effect of Everolimus on Heterogenous Renal Cancer Cells Populations Including Renal Cancer Stem Cells.
Kornakiewicz A; Czarnecka AM; Khan MI; Krasowski P; Kotrys AV; Szczylik C
Stem Cell Rev Rep; 2018 Jun; 14(3):385-397. PubMed ID: 29508215
[TBL] [Abstract][Full Text] [Related]
7. ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma.
Carew JS; Esquivel JA; Espitia CM; Schultes CM; Mülbaier M; Lewis JD; Janssen B; Giles FJ; Nawrocki ST
PLoS One; 2012; 7(1):e31120. PubMed ID: 22295124
[TBL] [Abstract][Full Text] [Related]
8. Decreased apoptosis repressor with caspase recruitment domain confers resistance to sunitinib in renal cell carcinoma through alternate angiogenesis pathways.
Gobe GC; Ng KL; Small DM; Vesey DA; Johnson DW; Samaratunga H; Oliver K; Wood S; Barclay JL; Rajandram R; Li L; Morais C
Biochem Biophys Res Commun; 2016 Apr; 473(1):47-53. PubMed ID: 26995091
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines.
Kawamoto K; Hirata H; Kikuno N; Tanaka Y; Nakagawa M; Dahiya R
Int J Cancer; 2008 Aug; 123(3):535-42. PubMed ID: 18404682
[TBL] [Abstract][Full Text] [Related]
10. PON1 hypermethylation is associated with progression of renal cell carcinoma.
Li X; Yu Q
J Cell Mol Med; 2019 Oct; 23(10):6646-6657. PubMed ID: 31400051
[TBL] [Abstract][Full Text] [Related]
11. Tetrandrine triggers apoptosis and cell cycle arrest in human renal cell carcinoma cells.
Chen T; Ji B; Chen Y
J Nat Med; 2014 Jan; 68(1):46-52. PubMed ID: 23564030
[TBL] [Abstract][Full Text] [Related]
12. Endothelin-1 promotes cell survival in renal cell carcinoma through the ET(A) receptor.
Pflug BR; Zheng H; Udan MS; D'Antonio JM; Marshall FF; Brooks JD; Nelson JB
Cancer Lett; 2007 Feb; 246(1-2):139-48. PubMed ID: 16581180
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-451 regulates chemoresistance in renal cell carcinoma by targeting ATF-2 gene.
Sun X; Lou L; Zhong K; Wan L
Exp Biol Med (Maywood); 2017 Jun; 242(12):1299-1305. PubMed ID: 28429654
[TBL] [Abstract][Full Text] [Related]
14. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.
Reu FJ; Bae SI; Cherkassky L; Leaman DW; Lindner D; Beaulieu N; MacLeod AR; Borden EC
J Clin Oncol; 2006 Aug; 24(23):3771-9. PubMed ID: 16801630
[TBL] [Abstract][Full Text] [Related]
15. Targeting Germ Cell Tumors with the Newly Synthesized Flavanone-Derived Compound MLo1302 Efficiently Reduces Tumor Cell Viability and Induces Apoptosis and Cell Cycle Arrest.
Lobo J; Cardoso AR; Miranda-Gonçalves V; Looijenga LHJ; Lopez M; Arimondo PB; Henrique R; Jerónimo C
Pharmaceutics; 2021 Jan; 13(1):. PubMed ID: 33430420
[TBL] [Abstract][Full Text] [Related]
16. Topotecan (Hycamtin) responsiveness in human renal carcinoma cell lines of the clear cell and papillary types.
Ramp U; Mahotka C; Kalinski T; Ebel E; Gabbert HE; Gerharz CD
Anticancer Res; 2001; 21(5):3509-17. PubMed ID: 11848517
[TBL] [Abstract][Full Text] [Related]
17. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.
Morris MR; Gentle D; Abdulrahman M; Maina EN; Gupta K; Banks RE; Wiesener MS; Kishida T; Yao M; Teh B; Latif F; Maher ER
Cancer Res; 2005 Jun; 65(11):4598-606. PubMed ID: 15930277
[TBL] [Abstract][Full Text] [Related]
18. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
[TBL] [Abstract][Full Text] [Related]
19. Folliculin deficient renal cancer cells exhibit BRCA1 A complex expression impairment and sensitivity to PARP1 inhibitor olaparib.
Zhang Q; Xu Y; Zhang Z; Li J; Xia Q; Chen Y
Gene; 2021 Feb; 769():145243. PubMed ID: 33069804
[TBL] [Abstract][Full Text] [Related]
20. Alterations in enhancer of zeste homolog 2, matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression are associated with ex vivo and in vitro bone metastasis in renal cell carcinoma.
Wang J; Ren Y; Guo X; Cheng H; Ye Y; Qi J; Yang C; You H
Mol Med Rep; 2015 May; 11(5):3585-92. PubMed ID: 25571919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
